Epstein-Barr virus infection in adult renal transplant recipients

American Journal of Transplantation

Volumn 14, Issue 7, 2014, Pages 1619-1629

  Morton, M ^a   Coupes, B ^a   Roberts, S A ^b   Johnson, S L ^a   Klapper, P E ^a,c   Vallely, P J ^c   Picton, M L ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Epstein Barr virus; immunosuppression; PTLD; renal transplantation

Indexed keywords

AZATHIOPRINE; EPSTEIN BARR VIRUS ANTIGEN 1; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VIRUS CAPSID ANTIGEN; VIRUS DNA; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ADULT DISEASE; AGED; ARTICLE; CROSS-SECTIONAL STUDY; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYMPTOM ASSESSMENT; TIME; VERY ELDERLY; ADOLESCENT; EPSTEIN-BARR VIRUS INFECTIONS; GENETICS; GLOMERULUS FILTRATION RATE; IMMUNOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; PROGNOSIS; RISK FACTOR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CROSS-SECTIONAL STUDIES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 84902987527     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12703     Document Type: Article

References (42)

1. Parker A, Bowles K, Bradley J, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2010; 149: 675-692.
2. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): Prevention and treatment. Nephrol Dial Transplant 2002; 17: 31-33, 35-36.
3. KDIGO. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-S155.
4. Green M, Michaels M., Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 2013; 13 (Suppl 3): S41-S54.
5. Martin S, Dodson B, Wheeler C, Davis J, Pesavento T, Bumgardner G., Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients. Am J Transplant 2011; 11: 1058-1063.
6. Bamoulid J, Courivaud C, Coaquette A, et al. Subclinical Epstein-Barr virus viremia among adult renal transplant recipients: Incidence and consequences. Am J Transplant 2013; 13: 656-662.
7. Lee T, Savoldo B, Rooney C, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222-2228.
8. Morton M, Coupes B, Roberts S, et al. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients. Transplantation 2013; 95: 470-478.
9. Caillard S, Lamy F, Quelen C, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: Report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012; 12: 682-693.
10. Niesters HGM, Van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus ADME., Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000; 38: 712-715.
11. Allen U, Preiksaitis J., Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant 2013; 6: 107-120.
12. Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008; 8: 442-445.
13. Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH., Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant 2012; 26: 741-747.
14. San-Juan R, De Dios B, Navarro D, et al. Epstein-Barr virus DNAemia is an early surrogate marker of the net state of immunosuppression in solid organ transplant recipients. Transplantation 2012; 95: 688-693.
15. Sato T, Fujieda M, Tanaka E, et al. Monitoring of Epstein-Barr virus load and antibody in pediatric renal transplant patients. Pediatr Int 2008; 50: 454-458.
16. Tsai DE, Nearey M, Hardy CL, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant 2002; 2: 946-954.
17. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G., Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 2009; 13: 319-323.
18. Holmes M, Caplin B, Atkinson C, et al. Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: Role of mycophenolate mofetil. Transplantation 2009; 87: 852-856.
19. Haque T, Thomas JA, Parratt R, Hunt BJ, Yacoub MH, Crawford DH., A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events. Transplantation 1997; 64: 1028-1034.
20. Li L, Chaudhuri A, Weintraub LA, et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11: 187-195.
21. Van Esser JW, Niesters HG, Van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369.
22. Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005; 5: 566-572.
23. Sampaio M, Cho Y, Shah T, Bunnapradist S, Hutchinson I., Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 2012; 93: 73-81.
24. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K., Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243.
25. Birkeland SA, Hamilton-Dutoit S., Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se ? Transplantation 2003; 76: 984-988.
26. Funch DP, Ko HH, Travasso J, et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 2005; 80: 1174-1180.
27. Evens AM, Choquet S, Kroll-Desrosiers AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): An international report of 84 cases in the modern era. Am J Transplant 2013; 13: 1512-1522.
28. Boersma MN, Van der Zanden A, Laverman GD, Sanders JS, De Vries PAM., Epstein-Barr virus-positive post-transplant lymphoproliferative disorder of the central nervous system, after renal transplantation with a discrepancy in viral load between peripheral blood and cerebrospinal fluid. Transplant Int 2012; 25: e113-e116.
29. Rickinson A, Kieff E., Epstein-Barr virus. In:, Snipe DM, Howley PM, eds. Field's virology. Lippincott, Williams & Wilkins, 2006, pp. 2657-2701.
30. Njie R, Bell A, Jia H, et al. The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. J Infect Dis 2009; 199: 31-38.
31. Ahya VN, Douglas LP, Andreadis C, et al. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant 2007; 26: 839-844.
32. Smith JM, Corey L, Bittner R, et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21: 1579-1586.
33. Tsai D, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: Results of a two-arm prospective trial. Am J Transplant 2008; 8: 1016-1024.
34. Opelz G, Daniel V, Naujokat C, Dohler B., Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962-967.
35. Sampaio M, Cho Y, Shah T, Bunnapradist S, Hutchinson I., Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant 2012; 27: 2971-2979.
36. Van Leeuwen MT, Grulich AE, Webster AC, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009; 114: 630-637.
37. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604-1611.
38. Tanaka E, Sato T, Ishihara M, et al. Asymptomatic high Epstein-Barr viral load carriage in pediatric renal transplant recipients. Pediatr Transplant 2011; 15: 306-313.
39. Toyoda M, Moudgil A, Warady BA, Puliyanda DP, Jordan SC., Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. Pediatr Transplant 2008; 12: 778-784.
40. Blaes AH, Cao Q, Wagner JE, Jo-Anne HY, Weisdorf DJ, Brunstein CG., Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after anti-thymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010; 16: 287-291.
41. Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001; 72: 1012-1019.
42. Tsai D, Hardy C, Tomaszewski J, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088.